Key points
- FY26 revenue was $269.5 million, down 0.9%
- Underlying EBITDA was $53.4 million, down 19.5%
- Domestic stimulated cycle market share increased to 20.2% in 2H26
- International revenue up 15%, EBITDA up 10%
- Approved three-year strategic plan 'Nurture 2030'
Full summary
Monash IVF Group Ltd announced its FY26 financial results, reporting revenue of $269.5 million and Underlying EBITDA of $53.4 million. The results were below the company's June 2026 guidance due to domestic stimulated cycle volume and market share pressures in the first half. However, momentum and market share improved in the second half, with domestic stimulated cycle market share increasing to 20.2%. International revenue grew by 15% to $21.2 million, and EBITDA increased by 10% to $4.2 million. The company also completed strategic capital investments, strengthened its leadership team, and launched a three-year strategic plan called 'Nurture 2030'. The company expects financial performance to strengthen in FY27 with improving market conditions and continued growth in international, genetics, and diagnostics businesses.
Guidance
FY26 revenue: $269.5 million, Underlying EBITDA: $53.4 million
Outlook
FY27 expected to strengthen with improving market conditions, continued growth in international, genetics, and diagnostics businesses, and embedded productivity and efficiency measures.